Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
25.47
+0.01 (0.04%)
At close: Dec 5, 2025, 4:00 PM EST
25.25
-0.22 (-0.86%)
After-hours: Dec 5, 2025, 5:48 PM EST
Lyell Immunopharma Employees
Lyell Immunopharma had 300 employees as of December 31, 2024. The number of employees increased by 76 or 33.93% compared to the previous year.
Employees
300
Change (1Y)
76
Growth (1Y)
33.93%
Revenue / Employee
$137
Profits / Employee
-$1,085,533
Market Cap
535.76M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 300 | 76 | 33.93% |
| Dec 31, 2023 | 224 | -50 | -18.25% |
| Dec 31, 2022 | 274 | 55 | 25.11% |
| Dec 31, 2021 | 219 | 29 | 15.26% |
| Dec 31, 2020 | 190 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
LYEL News
- 23 days ago - Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025 - GlobeNewsWire
- 25 days ago - Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer - GlobeNewsWire
- 4 weeks ago - Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition - GlobeNewsWire
- 3 months ago - Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee - GlobeNewsWire
- 3 months ago - Lyell Immunopharma Announces Participation in September Investor Conferences - GlobeNewsWire
- 4 months ago - Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025 - GlobeNewsWire
- 4 months ago - Lyell Immunopharma Announces up to $100 Million Equity Private Placement - GlobeNewsWire
- 4 months ago - Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement - Seeking Alpha